Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

NCT01441973 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Smoldering Multiple Myeloma

Interventions

BIOLOGICAL: Elotuzumab (BMS-901608; HuLuc63)

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]